FibroGen (NASDAQ:FGEN) has dosed first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
Approx. 565 subjects will be enrolled into the global study. The primary endpoint is the change in forced vital capacity from baseline. Subjects who complete the 52-week study may be eligible for rollover into a separate study offering, extension treatment with pamrevlumab.
Pamrevlumab is an antibody developed to inhibit the activity of connective tissue growth factor.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.